Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort.
about
Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapyFetal death in utero and miscarriage in a patient with Crohn's disease under therapy with ustekinumab: case-report and review of the literature.Efficacy and safety of ustekinumab in the induction therapy of TNF-α-refractory Crohn's disease patients: a systematic review and meta-analysis.Positioning ustekinumab in Crohn's disease: from clinical evidence to clinical practice.Emerging biologics in inflammatory bowel disease.IL-23 Blockade for Crohn s disease: next generation of anti-cytokine therapy.Crohn's disease diagnosis, treatment approach, and management paradigm: what the radiologist needs to know.Ustekinumab use in Crohn's disease: a Canadian tertiary care centre experience.Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort.Editorial: accumulating data about ustekinumab in refractory Crohn's disease in real world experience.Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience.Clinical utility of ustekinumab in Crohn's disease.Pharmacological Approach to the Management of Crohn's Disease Patients with Perianal Disease.Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study.Medical and surgical management of perianal Crohn's disease.Cyclophosphamide Pulse Therapy in Severe Refractory Crohn's Disease: A Retrospective Multicenter Case SeriesPerianal Fistulas in Patients With Crohn's Disease, Part 1: Current Medical Management
P2860
Q28067631-8601D5D5-6395-4805-9930-9E2BE157B043Q33815262-52921B36-116B-4E12-A52F-E3966996AEBDQ38702997-42CC316D-36A6-4F36-B790-FE2D8454214FQ38748380-DFA0F08F-BC8D-4307-A7A1-AEAB83C6B6D1Q39004625-2B4A752A-E4F1-4C89-A8D9-BF2BE9CA42C8Q39032463-FB197D64-F9BF-4060-B1DA-2E7BD2AC4445Q39140194-7E24A889-67CE-465A-9579-C35CFDC5AC54Q48014899-9841DA50-B802-42B5-AE02-F1FC67E66DF0Q48172992-4FFE115F-36C8-4C66-A780-73793194172FQ48267364-A5663D32-4DDD-4235-AE60-98D4C013B79FQ48282663-E0B08A60-651A-4776-8028-F461385F43B1Q49218809-1E1597E1-075E-4920-9F98-3FBD10941AD6Q50012048-B3C4EFD0-4C09-4CC1-8D43-F2709CD1C445Q50782815-4AC8FFAB-87DF-405A-BACC-3A41E737DCE3Q55103450-E148D10A-AB96-4625-8A07-BA8C5B5182C5Q56968600-4F7D3493-0121-4A42-BDD2-4670670C58F0Q57301026-8EF869CE-DD9A-456A-A40B-2E38EF531DC8
P2860
Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Ustekinumab for the Treatment ...... Multicentre Open-label Cohort.
@en
Ustekinumab for the Treatment ...... Multicentre Open-label Cohort.
@nl
type
label
Ustekinumab for the Treatment ...... Multicentre Open-label Cohort.
@en
Ustekinumab for the Treatment ...... Multicentre Open-label Cohort.
@nl
prefLabel
Ustekinumab for the Treatment ...... Multicentre Open-label Cohort.
@en
Ustekinumab for the Treatment ...... Multicentre Open-label Cohort.
@nl
P2093
P2860
P50
P1476
Ustekinumab for the Treatment ...... Multicentre Open-label Cohort
@en
P2093
Albert Villoria
Carlos Taxonera
Cristina Suarez
Daniel Ginard
Javier Martínez-González
Javier P Gisbert
Mariam Aguas
Mónica Sierra
Sam Khorrami
Valle García-Sánchez
P2860
P304
P356
10.1097/MIB.0000000000000842
P577
2016-07-01T00:00:00Z